Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

PharmaCoLogic: Preclinical Cardiac Drug Screening


Technology Benefits

Predictive computer based model Able to predict drug effects over multiple time and spatial scales


Technology Application

Preclinical drug screening Drug rehabilitation Drug induced cardiac arrhythmias Drug interaction with inherently coexistent risk factors


Detailed Technology Description

Cardiotoxicity is one of the most common and dangerous risks in the development of new drugs. Due to the association between prolonged QT intervals and drug-induced proarrhythmias, QT intervals have become widely accepted as markers for cardiac arrhythmia. QT intervals, however, have become problematic as they are neither sensitive nor selective in cardiotoxicity identification. This results in the unnecessary elimination of potentially useful drugs. Researchers at the University of California, Davis have developed PharmaCoLogic: a computer based multiscale model to predict the effects of developmental drugs and drug induced cardiotoxicity. The model uses dynamic interactions of drugs and ion channels (at the atomic level) to generate kinetic function parameters. These parameters are then integrated into predictive models at the channel, cell and tissue scales, to expose fundamental arrhythmia vulnerabilities and complex emergent behaviors. The model can be used to predict inherently coexistent risk factors during preclinical drug screening and drug rehabilitation.


Others

Tech ID/UC Case

27335/2016-665-0


Related Cases

2016-665-0


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View